Drugs in Dev. Infections and Infectious Diseases
Undisclosed
Ireland 
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial objective is the effect of VASCEPA vs usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis.
Product Name : Vascepa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 got clearance from Health Canada.
Product Name : INOmax
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OC43 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Orphan’s Cathal Friel on firm’s “milestone” human coronavirus challenge study (ORPH)
Details : For this human challenge study model, the common coronavirus strains such as OC43 and 229E, will provide an effective tool to obtain fast proof-of-concept data against this family of viruses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : OC43 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
